341636.pdf (2.65 MB)
Targeting the HGF-cMET Axis in Hepatocellular Carcinoma
journal contribution
posted on 2014-01-03, 00:00 authored by Neeta K. Venepalli, Laura GoffUnder normal physiological conditions, the hepatocyte growth factor (HGF) and its receptor, the MET transmembrane tyrosine kinase (cMET), are involved in embryogenesis, morphogenesis, and wound healing. The HGF-cMET axis promotes cell survival, proliferation, migration, and invasion via modulation of epithelial-mesenchymal interactions. Hepatocellular cancer (HCC) is the third most common cause of worldwide cancer-related mortality; advanced disease is associated with a paucity of therapeutic options and a five-year survival rate of only 10%. Dysregulation of the HGF-cMET pathway is implicated in HCC carcinogenesis and progression through activation of multiple signaling pathways; therefore, cMET inhibition is a promising therapeutic strategy for HCC treatment. The authors review HGF-cMET structure and function in normal tissue and in HCC, cMET inhibition in HCC, and future strategies for biomarker identification.
History
Publisher Statement
Copyright © 2013 N. K. Venepalli and L. Goff. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2013 by Hindawi Publishing Corporation, International Journal of Hepatology.Publisher
Hindawi Publishing CorporationLanguage
- en_US
issn
2090-3448Issue date
2013-03-01Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC